SGK Inhibitor

HaloPROTAC-E is a potent Halo PROTAC degrader that reversibly induces degradation of two Halo-tagged endoplasmic reticulum-localized proteins, SGK3 and VPS34, with a DC₅₀ of 3-10 nM. HaloPROTAC-E significantly and selectively induces degradation of endogenous VPS34 complexes (VPS34, VPS15, Beclin1, and ATG14) labeled with Halo and inhibits autophagy.

SI-113 is a SGK1 inhibitor, with an IC₅₀ of 600 nM. SI113 induces autophagy.

SGK1-IN-4 (compound 17a) is a highly selective, orally active SGK1 inhibitor. SGK1-IN-4 can be used for osteoarthritis research.

Sgk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sgk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGK1-IN-7 is a blood-brain barrier-permeable SGK1 inhibitor with an IC₅₀ of 0.72 μM. SGK1-IN-7 reduces the phosphorylation level of TAU protein at the Ser396 and Ser214 epitopes. SGK1-IN-7 antagonizes the toxicity induced by Okadaic acid (HY-N6785). SGK1-IN-7 can be used in the research of Alzheimer's disease.

SGK1-IN-8 (compound 55) is a SGK1 and GSK3β inhibitor, with an IC₅₀ of 0.11 μM against human SGK1 and an IC₅₀ of 3.39 μM against human GSK3β. SGK1-IN-8 inhibits the catalytic activities of SGK1 and GSK3β, and reduces the phosphorylation level of TAU protein at the Ser214 site. SGK1-IN-8 is available for the research of Alzheimer's disease.

Sgk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sgk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sgk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sgk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

SGK1 Human Pre-designed siRNA Set A contains three designed siRNAs for SGK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GSK 650394 (Standard) is the analytical standard of GSK 650394. This product is intended for research and analytical applications. GSK 650394 is a novel SGK inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.

EMD638683 (Standard) is the analytical standard of EMD638683. This product is intended for research and analytical applications. EMD638683 is an orally effective SGK1 inhibitor with an IC₅₀ of 3 μM. EMD638683 exhibits strong inhibition against SGK1, moderate inhibition against SGK2 and SGK3, and shows excellent selectivity for other AGC kinase family members. EMD638683 has antihypertensive activity by inhibiting SGK1, and independently of the blood pressure-lowering effect, it effectively prevents heart inflammation and fibrosis caused by hypertension by inhibiting the cardiac NLRP3 inflammation body/ IL-1β axis. EMD638683 promotes apoptosis of colon cancer cells and sensitizes radiotherapy. EMD638683 (S-Form) can be used in research related to hypertension, hypertensive heart damage, and colon cancer.